Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Revance Therapeutics

Revance Therapeutics reported $77.98M in Current Liabilities for its fiscal quarter ending in March of 2023.

Current Liabilities Change
Cara Therapeutics CARA:US USD 16.68M 6.78M
Coherus Biosciences CHRS:US USD 123.41M 15.29M
Eli Lilly LLY:US USD 16.01B 1.13B
Endo International ENDP:US USD 606.64M 82.98M
Horizon Pharma HZNP:US USD 884.89M 64.25M
J&J JNJ:US USD 60.37B 4.57B
Neurocrine Biosciences NBIX:US USD 374.1M 163.6M
P&G PG:US USD 38.03B 716M
Pacira PCRX:US USD 98.7M 49.08M
Revance Therapeutics RVNC:US USD 77.98M 2.3M
Supernus Pharmaceuticals SUPN:US USD 731.54M 43.59M